Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

THOMAS H BRANNAGAN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1245327337
CMS profile
10853
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$21,280.50

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

THOMAS H BRANNAGAN

NPI 1245327337 · CMS profile ID 10853

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1245327337?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
THOMAS H BRANNAGAN, NPI 1245327337, CMS profile ID 10853. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245327337?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). THOMAS H BRANNAGAN, NPI 1245327337, CMS profile ID 10853. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245327337?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
THOMAS H BRANNAGAN, NPI 1245327337, CMS profile ID 10853, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1245327337?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $21,280.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–59 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ARGENX US, INC. $125.0004/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240424406 CMS
Grifols Shared Services North America, Inc. $294.7104/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249583518 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.2604/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223859671 CMS
Grifols USA, LLC $29.6003/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249583520 CMS
AstraZeneca Pharmaceuticals LP $1,611.0003/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206309684 CMS
AstraZeneca Pharmaceuticals LP $56.6702/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206863373 CMS
ARGENX US, INC. $32.7702/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240420805 CMS
AstraZeneca Pharmaceuticals LP $19.6902/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207009484 CMS
Grifols USA, LLC $23.6501/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249583516 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $65,920.11 142
PY2020 $7,328.16 18
PY2021 $13,333.78 14
PY2022 $17,963.91 34
PY2023 $1,207.22 21
PY2024 $21,737.85 44
PY2025 $21,280.50 59

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $231,408.29 20
PY2024 Principal investigator $60,518.75 17
PY2023 Principal investigator $192,549.32 34
PY2022 Principal investigator $91,436.68 21
PY2021 Principal investigator $136,867.33 40
PY2020 Principal investigator $114,514.62 22
PY2019 Recipient $1,384.65 12
PY2019 Principal investigator $199,749.26 22

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

20 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $6,615.00 11/10/2025 Non-covered Recipient Entity
The Trustees Of Columbia University In The City Of New York
A Phase 2, Multicenter, Open-label, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1226135940
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $810.00 10/29/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184253568
Principal investigator 1 SANOFI US SERVICES INC. $4,740.00 10/06/2025 Non-covered Recipient Entity
The Trustees Of Columbia University In The City Of New York
A Phase 3, Doubleblind, Placebocontrolled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy No dispute reported 06/30/2026 1226135938
Principal investigator 1 Janssen Research & Development, LLC $1,485.00 08/06/2025 Non-covered Recipient Entity
The Trustees Of Columbia Univ In The City Of New York
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1175249372
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 08/06/2025 Non-covered Recipient Entity
The Trustees Of Columbia Univ In The City Of New York
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1175251891
Principal investigator 1 Janssen Research & Development, LLC $4,050.00 08/06/2025 Non-covered Recipient Entity
The Trustees Of Columbia Univ In The City Of New York
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1175252405
Principal investigator 1 Janssen Research & Development, LLC $2,970.00 08/06/2025 Non-covered Recipient Entity
The Trustees Of Columbia Univ In The City Of New York
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1175252912
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $27,237.85 07/18/2025 Non-covered Recipient Entity
COLUMBIA PRESBYTERIAN THE NEUROLOGICAL INSTITUTE OF NEW YORK
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214125546
Principal investigator 1 SANOFI US SERVICES INC. $3,000.00 07/02/2025 Non-covered Recipient Entity
The Trustees Of Columbia University In The City Of New York
A Phase 3, Doubleblind, Placebocontrolled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy No dispute reported 06/30/2026 1226135916
Principal investigator 1 SANOFI US SERVICES INC. $24,277.50 06/16/2025 Non-covered Recipient Entity
The Trustees Of Columbia University In The City Of New York
A Phase 3, Doubleblind, Placebocontrolled Study Evaluating Efficacy and Safety of Riliprubart in Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy No dispute reported 06/30/2026 1226135894
Principal investigator 1 SANOFI US SERVICES INC. $1,848.00 06/16/2025 Covered Recipient Teaching Hospital
Uci Medical Center
PHASE 3 Study in Standard of Care Treated Patients with CIDP (Placebo & IVIG comparator) No dispute reported 06/30/2026 1226148449
Principal investigator 1 Alnylam Pharmaceuticals Inc. $12,063.00 05/29/2025 Non-covered Recipient Entity
Columbia University Irving Medical Center
HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) No dispute reported 06/30/2026 1215521926
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,175.00 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184199131
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,577.50 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184199133
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,725.00 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184199135
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 05/28/2025 Non-covered Recipient Entity
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients With Postural Orthostatic Tachycardia Syndrome No dispute reported 06/30/2026 1184199137
Principal investigator 1 ARGENX US, INC. $3,700.00 03/06/2025 Non-covered Recipient Entity
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1237158680
Principal investigator 1 SANOFI US SERVICES INC. $23,277.50 02/10/2025 Non-covered Recipient Entity
The Trustees Of Columbia University Y In The City Of New York Columbia Technology Ventures
PHASE 3 Study in Standard of Care Treated Patients with CIDP (Placebo & IVIG comparator) No dispute reported 06/30/2026 1226086781
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $81,741.94 02/01/2025 Non-covered Recipient Entity
COLUMBIA PRESBYTERIAN THE NEUROLOGICAL INSTITUTE OF NEW YORK
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214123508
Principal investigator 1 SANOFI US SERVICES INC. $6,615.00 01/06/2025 Non-covered Recipient Entity
The Trustees Of Columbia University In The City Of New York
A Phase 2, Multicenter, Open-label, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of BIVV020 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1226135847